my thoughts are we probably won't be included in any existing tests.
the 2 possible key accounts are merck with their lateral flow development services which will be for new test that will have Merck's help in developing and be manufactured in Ireland and the US.
https://www.linkedin.com/posts/merc...tm_source=share&utm_medium=member_desktopthe other being in multiplex tests. don't know who the 2nd will be, serum institute of India or abbot maybe
since the covid testing windfall for POC tests, they are being much more accepted and a growth area appears to be in multiplexing. an area we claimed that anteobind helped with the tests sensistivity
(thanks to j&b85 for the links to the following he posted)
we had the Serum Institute of India and MHRA (UK's - FDA/ TGA) in Oct 22 do a joint study on a 5 multiplex test using luminex beads and Anteobind which seems to be done to set levels of multiplex standards
https://assets.researchsquare.com/f...-54f3-450e-a9b1-03990ecadc91.pdf?c=1671468269then in June 23 did the same test involving FDA EMA and ICH M10 guidelines and parameters.
https://www.frontiersin.org/articles/10.3389/fimmu.2023.1190404/fullthen recently I have seen a paper in preprint that tested anteobind in a multiplex test that gives results of 7x - 46x gains in sensitivity
a lot of muliplex tests are only in development stages, with anteobinds reduction in cost and increase in sensitivity we are in a pretty good position to be "anteo inside" a high % of these new multiplex tests.
mightn't be a huge revenue earner to begin with but seeing some predicted volumes of tests in the future it could be a very substantial earner in the future.
IMO, DYOR etc etc....
